Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll PTEN hamartoma tumor syndromes Blumenthal GM; Dennis PAEur J Hum Genet 2008[Nov]; 16 (11): 1289-300The PTEN hamartoma tumor syndromes (PHTS) are a collection of rare clinical syndromes characterized by germline mutations of the tumor suppressor PTEN. These syndromes are driven by cellular overgrowth, leading to benign hamartomas in virtually any organ. Cowden syndrome (CS), the prototypic PHTS syndrome, is associated with increased susceptibility to breast, thyroid, and endometrial cancer. PTEN is located on chromosome 10q22-23 and negatively regulates the prosurvival PI3K/Akt/mTOR pathway through its lipid phosphatase activity. Loss of PTEN activates this pathway and leads to increased cellular growth, migration, proliferation, and survival. Clinical management of patients with PHTS, particularly those with CS, should include early and frequent screening, surveillance, and preventive care for associated malignancies. Concomitant with improved understanding of the biology of PTEN and the PI3K/Akt/mTOR pathway, inhibitors of this pathway are being developed as anticancer agents. These medications could have applications for patients with PHTS, for whom no medical options currently exist.|*Hamartoma Syndrome, Multiple/drug therapy/genetics/metabolism[MESH]|*Mutation[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Cell Movement[MESH]|Cell Proliferation[MESH]|Cell Survival[MESH]|Chromosomes, Human, Pair 10/genetics/metabolism[MESH]|Female[MESH]|Humans[MESH]|Male[MESH]|PTEN Phosphohydrolase/genetics/*metabolism[MESH]|Phosphatidylinositol 3-Kinases/genetics/metabolism[MESH]|Protein Kinases/genetics/metabolism[MESH]|Proto-Oncogene Proteins c-akt/genetics/metabolism[MESH]|Signal Transduction[MESH]|TOR Serine-Threonine Kinases[MESH] |